Anti-Vascular Endothelial Growth Factor Therapeutics Market Trends 2025-2034: Insights into Growth and Strategic Opportunities Ahead
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Anti-Vascular Endothelial Growth Factor Therapeutics Market’s Growth Rate Evolve Over the Forecast Period to 2034?
In recent times, the anti-vascular endothelial growth factor therapeutics market has seen a slight expansion. The market is projected to grow from $12.2 billion in 2024 to $12.31 billion in 2025, with a compound annual growth rate (CAGR) of 1.0%. This growth over the historical period can be traced back to an increase in age-related macular degeneration, a rise in diabetic retinopathy incidences, advancements in diagnosing retinal disease, effective clinical results, and a shift towards outpatient treatment.
The market for anti-vascular endothelial growth factor therapeutics is predicted to witness stable growth in the coming years, reaching “$13.49 billion by 2029 with a CAGR of 2.3%. This projected growth during the forecast period is linked to factors such as an aging population and the prevalence of ocular diseases, the broadening use of these therapeutics in retinal disorders, the emergence of next-generation therapies, the increasing focus on early interventions, as well as global health initiatives and improved access to treatment. The predominant trends for this forecast period encompass their increased use in cancer treatment, a shift towards combination therapies in ophthalmology, the investigation of biosimilar editions, studies into resistance mechanisms and the incorporation of imaging technologies.
What Key Drivers Are Accelerating the Growth of the anti-vascular endothelial growth factor therapeutics Market During the Forecast Period?
The rise in the frequency of eye-related illnesses is anticipated to accelerate the expansion of the anti-vascular endothelial growth factor therapeutics market. The commonly found eye conditions or diseases in a given population define the frequency of ophthalmic diseases. Anti-vascular endothelial growth factor (VEGF) treatments effectively manage diseases like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, thereby lowering the incidence of eye diseases. For instance, the World Health Organization stated in October 2022 that approximately 2.2 billion individuals globally suffer from near or distant vision impairment, with 1 billion having near or distant vision troubles. Additionally, there are 88.4 million individuals with refractive errors, 94 million with cataracts, 8 million with age-related macular degeneration, and about 3.9 million with diabetic retinopathy. Consequently, the surge in eye-related illnesses is fueling the growth of the anti-vascular endothelial growth factor therapeutics market.
Request Your Free Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Who Are the Influential Players Reshaping the Anti-Vascular Endothelial Growth Factor Therapeutics Market Landscape?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include:
• F. Hoffmann-La Roche AG_x000D_
• Biogen Inc._x000D_
• Pfizer Inc._x000D_
• Coherus BioSciences Inc._x000D_
• Eli Lilly and Company_x000D_
What New and Evolving Trends Are Having a Lasting Impact on the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Progress in therapeutics is a significant trend gaining traction in the anti-vascular endothelial growth factor therapeutics market. Companies active in this market are embracing cutting-edge therapeutics to maintain their market standing. For example, Ashvattha Therapeutics Inc., a US clinical-stage biopharmaceutical firm, unveiled phase 1 safety data in May 2022 for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates D-4517.2 therapy. This is a pioneering therapy designed to meet the unaddressed needs of DME conditions, and it is currently under development for self-administration via an autoinjector. The autoinjector D-4517.2 allows patients to administer the medication themselves on a monthly basis within their homes.
Pre-order Your Report for Quick and Easy Delivery!
What Are the Core Segments of the Anti-Vascular Endothelial Growth Factor Therapeutics Market, and How Do They Contribute to Growth?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Which Geographic Locations Are Critical to the Growth of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Defining Aspects of the Anti-Vascular Endothelial Growth Factor Therapeutics Market Landscape?
Anti-Vascular Endothelial Growth Factor (VEGF) therapeutics are drugs that inhibit the growth of blood vessels, commonly used in the treatment of ophthalmic diseases. These drugs inhibit vascular endothelial growth factors. It is utilized in the therapy of some tumors and in treating age-related macular degeneration.
Browse Through More Similar Reports By The Business Research Company:
Insecticides Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insecticides-global-market-report
Crop Protection Chemicals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/crop-protection-chemicals-global-market-report
Vector Control Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
